TipRanks
Baudax Bio (BXRXQ)
OTHER OTC:BXRXQ
US Market
BXRXQ
Baudax Bio
RESEARCH TOOLSreports

Baudax Bio (BXRXQ) Ratios

741 Followers

Baudax Bio Ratios

BXRXQ's free cash flow for Q3 2023 was $―. For the 2023 fiscal year, BXRXQ's free cash flow was decreased by $ and operating cash flow was $―. See a summary of the company’s cash flow.
Ratios
TTM
Dec 22Dec 21Dec 20Dec 19
Liquidity Ratios
Current Ratio
 0.30--- ―
Quick Ratio
 0.30--- ―
Cash Ratio
 0.25--- ―
Solvency Ratio
 -1.65--- ―
Operating Cash Flow Ratio
 -1.30--- ―
Short-Term Operating Cash Flow Coverage
 -4.96--- ―
Net Current Asset Value
$ -27.93M$ -27.93M$ -16.56M$ -46.81M$ ―
Leverage Ratios
Debt-to-Assets Ratio
 0.71--- ―
Debt-to-Equity Ratio
 -0.29--- ―
Debt-to-Capital Ratio
 -0.42--- ―
Long-Term Debt-to-Capital Ratio
 -0.07--- ―
Financial Leverage Ratio
 -0.41--- ―
Debt Service Coverage Ratio
 -6.00--- ―
Interest Coverage Ratio
 0.00--- ―
Debt to Market Cap
 1.63K--- ―
Interest Debt Per Share
 21.47--- ―
Net Debt to EBITDA
 -0.06 -0.06 0.15 0.28 ―
Profitability Margins
Gross Profit Margin
-452.32%---―
EBIT Margin
-2816.63%---―
EBITDA Margin
-2646.26%---―
Operating Profit Margin
-4476.99%---―
Pretax Profit Margin
-4633.18%---―
Net Profit Margin
-4633.18%---―
Continuous Operations Profit Margin
-4633.18%---―
Net Income Per EBT
100.00%---―
EBT Per EBIT
103.49%---―
Return on Assets (ROA)
-586.07%-586.07%-37.11%-110.72%―
Return on Equity (ROE)
1067.45%242.53%-149.47%514.22%―
Return on Capital Employed (ROCE)
497.14%497.14%-50.51%-147.79%―
Return on Invested Capital (ROIC)
974.83%974.83%-47.69%-144.88%―
Return on Tangible Assets
-743.77%-743.77%-67.08%-179.68%―
Earnings Yield
-177298976.22%-790630.89%-1610509.62%-25486549.02%―
Efficiency Ratios
Receivables Turnover
 3.79--- ―
Payables Turnover
 1.78--- ―
Inventory Turnover
 0.00--- ―
Fixed Asset Turnover
 1.80--- ―
Asset Turnover
 0.13--- ―
Working Capital Turnover Ratio
 -0.35--- ―
Cash Conversion Cycle
 -108.15 -108.15 710.75 -104.49 ―
Days of Sales Outstanding
 96.36 96.36 183.18 37.76 ―
Days of Inventory Outstanding
 0.00 0.00 746.72 627.58 ―
Days of Payables Outstanding
 204.50 204.50 219.15 769.83 ―
Operating Cycle
 96.36 96.36 929.90 665.34 ―
Cash Flow Ratios
Operating Cash Flow Per Share
 -83.81--- ―
Free Cash Flow Per Share
 -83.87--- ―
CapEx Per Share
 0.06--- ―
Free Cash Flow to Operating Cash Flow
 1.00--- ―
Dividend Paid and CapEx Coverage Ratio
 -1.39K--- ―
Capital Expenditure Coverage Ratio
 -1.39K--- ―
Operating Cash Flow Coverage Ratio
 -3.90--- ―
Operating Cash Flow to Sales Ratio
 -21.90--- ―
Free Cash Flow Yield
-638059.19%-374008.28%-4030388.11%-14969412.37%―
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 >-0.01--- ―
Price-to-Sales (P/S) Ratio
 <0.01--- ―
Price-to-Book (P/B) Ratio
 >-0.01--- ―
Price-to-Free Cash Flow (P/FCF) Ratio
 >-0.01--- ―
Price-to-Operating Cash Flow Ratio
 >-0.01--- ―
Price-to-Earnings Growth (PEG) Ratio
 <0.01--- ―
Price-to-Fair Value
 >-0.01--- ―
Enterprise Value Multiple
 -0.06--- ―
Enterprise Value
 1.86M 1.87M -7.36M -20.56M ―
EV to EBITDA
 -0.06 -0.06 0.15 0.28 ―
EV to Sales
 1.47 1.47 -6.81 -41.71 ―
EV to Free Cash Flow
 -0.07 -0.07 0.15 0.46 ―
EV to Operating Cash Flow
 -0.07 -0.07 0.15 0.47 ―
Tangible Book Value Per Share
 -79.52--- ―
Shareholders’ Equity Per Share
 -73.10--- ―
Tax and Other Ratios
Effective Tax Rate
 0.00--- ―
Revenue Per Share
 3.83--- ―
Net Income Per Share
 -177.30--- ―
Tax Burden
 1.00 1.00 1.00 1.00 ―
Interest Burden
 1.64 1.64 0.38 1.02 ―
Research & Development to Revenue
 3.06 3.06 2.89 18.43 ―
SG&A to Revenue
 19.01 0.00 0.00 0.00 ―
Stock-Based Compensation to Revenue
 1.10 1.10 4.43 18.95 ―
Income Quality
 0.47 0.47 2.49 0.58 ―
Currency in USD